SCHEMBL6300523

SCHEMBL6300523

CC(C)CC(CC(=O)N1CCC(c2ccccc2)C1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
POLB P06746 1/20 0.57
RAB9A P51151 9/20 0.52
LMNA P02545 2/20 0.52
MAPK1 P28482 2/20 0.50
SMN1; SMN2 Q16637 7/20 0.49
MAPT P10636 7/20 0.49
NPC1 O15118 6/20 0.49
GAA P10253 2/20 0.49
TP53 P04637 2/20 0.49
HTT P42858 2/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KCNH2 Q12809 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7102302 0.80 CTSS (0.47) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL12447962 0.77 ALDH1A1 (0.71) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL12447346 0.77 ALDH1A1 (0.71) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL25653340 0.77 ALDH1A1 (0.56) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL13005883 0.77 ALDH1A1 (0.56) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL19493589 0.76 ALDH1A1 (0.73) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL5870417 0.75 NOTUM (0.45) ALDH1A1POLBGAAKMT2AL3MBTL1
SCHEMBL2135668 0.75 ALDH1A1 (0.68) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL12282136 0.75 ALDH1A1 (0.68) ALDH1A1POLBRAB9ALMNAMAPK1
SCHEMBL16886312 0.74 RAB9A (0.58) ALDH1A1POLBRAB9ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6958358-B2 administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide AMURA THERAPEUTICS LIMITED (GB) 2005-10-25 US disclosed
US-20040127549-A1 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases AMURA THERAPEUTICS LIMITED (GB) 2004-07-01 US disclosed
US-20040106805-A1 Inhibitors of cruzipain and other cysteine proteases AMURA THERAPEUTICS LIMITED (GB) 2004-06-03 US disclosed
EP-1362042-A1 CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES Amura Therapeutics Limited (GB) 2003-11-19 EP disclosed
EP-1358176-A2 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES Amura Therapeutics Limited (GB) 2003-11-05 EP disclosed
WO-2002057249-A1 CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LIMITED (GB) 2002-07-25 WO disclosed
WO-2002057246-A2 INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES AMURA THERAPEUTICS LIMITED (GB) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127549-A1 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases CPN1, CTRL, CPA1 ALDH1A1 3042/4885POLB 2438/4885RAB9A 3524/4885
US-20040106805-A1 Inhibitors of cruzipain and other cysteine proteases CTRL, CPN1, CPA1 ALDH1A1 2942/4885POLB 2808/4885RAB9A 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.